Opus Genetics (IRD) Accumulated Expenses (2019 - 2026)

Opus Genetics (IRD) has 8 years of Accumulated Expenses data on file, last reported at $4.9 million in Q1 2026.

• Quarterly Accumulated Expenses fell 45.99% year-over-year to $4.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.9 million (down 45.99% YoY) and the FY2025 annual result came in at $4.5 million, down 44.91% from the prior year.
• Accumulated Expenses rose to $4.9 million in Q1 2026 per IRD's latest filing, from $4.5 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $9.1 million in Q1 2025 and bottomed at $233000.0 in Q1 2023.
• The 5-year median for Accumulated Expenses is $1.4 million (2025), against an average of $2.7 million.
• The widest annual swing landed in 2023, when Accumulated Expenses tumbled 83.58%; it then surged 1466.09% in 2024.
• Tracing IRD's Accumulated Expenses over 5 years: stood at $1.7 million in 2022, then sank by 55.29% to $753000.0 in 2023, then surged by 981.94% to $8.1 million in 2024, then tumbled by 44.91% to $4.5 million in 2025, then climbed by 9.58% to $4.9 million in 2026.
• Per Business Quant, the three latest IRD Accumulated Expenses figures stand at $4.9 million (Q1 2026), $4.5 million (Q4 2025), and $1.4 million (Q3 2025).

Peer Comparison